Retina Synthesis

In our latest update, we discuss the relative drying effects of faricimab and aflibercept in the treatment of diabetic macular edema with Dr. Roger Goldberg.

In our latest update, we discuss the use of artificial intelligence in the management of geographic atrophy with Professor Pearse Keane, Moorfields Eye Hospital, London.

In our latest update, we discuss the use of molecular techniques in the management of uveal melanoma with Dr. William Harbour, Professor and Chair, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.

We discuss the results of clinical trials studying  the use of faricimab in the treatment of retinal venous occlusion with Dr. Ramin Tadayoni, Professor of Ophthalmology University of Paris.

We review the one year results of a clinical trial using high dose aflibercept (8mg) for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Clinical Professor of Ophthalmology, USC Roski Eye Institute

We the discuss the use of wide field OCT angiography in the management of diabetic retinopathy, retinal vein occlusion, and pediatric retinal disease with Dr. Amir Kashani, Associate Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins School of Medicine

We review the use of anti-VEGF therapy for retinopathy of prematurity and in particular, the results of a clinical trial employing aflibercept with Dr. Darius Moshfeghi, Professor of Ophthalmology, Director of the Retina Service, Byers Eye Institute, Stanford University School of Medicine.

We discuss the use of home OCT and artificial intelligence in the management of anti-VEGF therapy of neovascular AMD with Dr. Anat Loewenstein, Director, Department of Ophthalmology, Tel Aviv Medical Center, Israel.

We discuss the use of suprachoroidal triamcinolone for the treatment of macular edema with Dr. Steven Yeh, Truhlsen Chair of Ophthalmology, University of Nebraska School of Medicine.

We discuss the use of the port delivery system for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Clinical Research, Sierra Eye Associates, Associate Clinical Professor, University of Nevada School of Medicine, Reno.

We discuss the suprachoroidal delivery of a tyrosinase kinase inhibitor and a gene therapy agent for the treatment of neovascular AMD with Dr. Mark Barakat, Assistant Clinical Professor of Ophthalmology, University of Arizona School of Medicine-Phoenix.

We discuss the use of microperimetry to assess treatment effects of anti-complement therapy (Apellis) of geographic atrophy with Dr. Nadia Waheed, Associate Professor of Ophthalmology, New England Eye Center, Tufts University School of Medicine.

We discuss the results of the RGX-314 study of subretinal gene therapy for neovascular AMD with Dr. Allen Ho, Professor of Ophthalmology, Wills Eye Hospital.

In our latest update, We discuss the results of a one year Phase I trial exploring the use of a tyrosinase inhibitor in an hydrogel implant for the treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology, USC Roski Eye Institute.

We discuss long term results of fixed dose anti-VEGF therapy for neovascular AMD with Dr. Ivan Suner, Retina Associates of Florida, Tampa, Florida.

We discuss the use of corticosteroids, in particular, the dexamethasone implant in the management of diabetic macular edema with Dr. Kevin Blinder, Professor of Clinical Ophthalmology at Washington University School of Medicine, The Retina Institute.

Thomas Albini, MD, Professor of Clinical Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute provides a comprehensive review of the etiology, diagnostic evaluation and treatment of retinal vasculitis.

We discuss the latest developments in diagnostic evaluation and treatment of eyes with central serous chorioretinopathy. with Roger Goldberg, MD, Bay Area Retina Associates, Walnut Creek, CA

Dr. Roger Goldberg from Bay Area Retina Associates, Walnut Creek, CA discusses the latest data regarding the use of faricimab in diabetic macular edema and neovascular AMD.

We discuss various strategies for treatment pauses in management of neovascular AMD, differences between bevacizumab and aflibercept in patients who can be successfully paused, and intra ocular biomarkers that may identify eyes in which treatment may be successful paused with Dr. Akrit Sodhi, Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine, Wilmer Eye Institute.

We review the current status of gene therapy for inherited retinal disorders, discussing preoperative evaluation, surgery, and follow up with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute.

We discuss the use of a suprachoroidal delivery system for delivery of tryrosinase kinase inhibitor for the treatment of neovascular AMD with Dr. Thomas Ciulla, Chief Development Officer, Chief Medical Officer, Clearside Biomedical.

We discuss a phase 2/3 trial employing tarcocimab reformer for branch and central vein occlusion with Michael Singer, MD, Clinical Professor University of Texas San Antonio Health Sciences Center.

We discuss the  use of intravitreal avacincaptad peg for the treatment of geographic atrophy in two randomized trials, Gather 1 and Gather 2 with Dr. Arshad Khanani, Sierra Eye Associates, Reno Nevada and Associate Clinical Professor University of Nevada Reno.

We discuss the role that en-face optical coherence tomography (OCT) can play in understanding the evolution of intermediate AMD and geographic atrophy with Dr. Philip Rosenfeld, Professor of Ophthalmology, Bascom Palmer Eye Institute and the University of Miami Miller School of Medicine.